Revenue

9 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended				Nine Months Ended
	June 30,				June 30,
(In thousands)	2021		2020		2021		2020
Medical Device
Product sales	$	5,493	$	5,763	$	15,464	$	16,240
Royalties		7,752		4,752		23,135		20,365
Research, development and other		2,466		2,353		7,212		7,215
License fees		1,044		7,646		15,047		10,402
Total Revenue — Medical Device		16,755		20,514		60,858		54,222
In Vitro Diagnostics
Product sales		6,591		6,224		18,505		17,491
Research, development and other		527		145		1,802		608
Total Revenue — In Vitro Diagnostics		7,118		6,369		20,307		18,099
Total Revenue	$	23,873	$	26,883	$	81,165	$	72,321

Contract assets totaled $7.0 million and $6.1 million as of June 30, 2021 and September 30, 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangements.